Toller Anfang, habs mir angesehen. Nur solltest Du / Ihr auch mal mit Monaten als angedachte Haltedauer ernst machen. Länger als 2 Tage oder mal ne Woche hast Du hier kaum geschafft, PRTL lässt grüssen.
Ich vermute, dass Deine Seite / Eure Seite viel mehr Beachtung findet, wenn Ihr langfristige Anlagen in Euer Musterdepot legt, bei denen die Besucher staunen, wieviel
Performance zusammengekommen ist. Shares wie TASR,JBSS,CYBD etc. gehörten in so ein Depot, ich habe dazu ausreichend geschrieben. Zu JBSS habs ich mir verkniffen, ich hab auch so genug getan an Empfehlungen.
Empfehlungen gibt es bald nur noch im Rahmen einer Investmentgemeinschaft, nicht mehr just for fun.
Also, summa summarum, ob Ihr mit kurzfristigen Trades Leser erreichen könnt, weiss ich nicht glaube ich aber eher nicht, es gibt schon godmode und andere Traderseiten, strategische Investments fände ich also spannender.
Fürs Traden und Zocken gibts ja den Wettbewerb hier, da mach ich auch ein komplett neues Depot auf für die 46 kw.
Es gibt ausser von Fortune auch andere Fast growing rankings.
Ein Wert der hier rein wandert ist z.B. PHST von der OTC, total verprügelt von 12 Dollar, aber nicht uninteressant.
Gruss E.
chart.bigcharts.com/bc3/quickchart/...56&mocktick=1&rand=2386"
Gruss E.
Pharsight Corporation Ranked Number 187 Fastest Growing Technology Company In North America on the 2003 Deloitte Technology Fast 500
Thursday, October 16, 2003 08:10 AM ET Printer-friendly version
MOUNTAIN VIEW, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST, news), a leading provider of science and information technology-based software and consulting services to optimize clinical drug development, announced today that it ranked Number 187 on the 2003 Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America. Rankings are based on average percentage revenue growth over five years, from 1998-2002. Pharsight grew 1,836 percent during this period.
Pharsight's president and chief executive officer, Shawn O'Connor, credits the demonstrated value that Pharsight's innovative software and services delivers to 18 of the top 20 pharmaceutical companies across the globe, for the company's 1,836 percent revenue growth over the past five years. "We are very honored to receive this recognition," said O'Connor. "This award acknowledges the hard work of our dedicated staff and their success in delivering value to and establishing a faithful client base for Pharsight."
"Because the Deloitte Technology Fast 500 measures sustained revenue growth over five years, being one of the 500 fastest growing technology companies in North America is an impressive achievement," said Mark Evans, national managing partner of Deloitte's Technology, Media & Telecommunications Group. "Pharsight deserves a lot of credit for its remarkable growth."
In addition to ranking on the Deloitte Technology Fast 500, Pharsight Corporation was also named on the Technology Fast 50, which is a ranking of the 50 fastest growing technology firms in Silicon Valley.
Fast 500 Selection and Qualifications
The Fast 500 list is compiled from Deloitte's 20 regional North American Fast 50 programs, nominations submitted directly to the Fast 500, and public company database research. To qualify for the Fast 500, entrants must have had 1998 operating revenues of at least $50,000 USD and $75,000 CD for the United States and Canada, respectively; and 2002 operating revenues must be at least $1 million USD or CD. Deloitte researchers examined financial statements to validate operating revenues.
Entrants must also be public or private companies headquartered in North America and must be a "technology company," defined as a company that owns proprietary technology that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology in a unique way does not qualify.
About Pharsight Corporation
Pharsight Corporation develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers' development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available on the World Wide Web at
www.pharsight.com. About Deloitte
Deloitte, one of the nation's leading professional services firms, provides audit, tax, financial advisory services and consulting through nearly 30,000 people in more than 80 U.S. cities. The firm is dedicated to helping its clients and its people excel. Known as an employer of choice for innovative human resources programs, Deloitte has been recognized as one of the "100 Best Companies to Work For in America" by Fortune magazine for six consecutive years. "Deloitte" refers to Deloitte & Touche LLP and affiliated entities. Deloitte is the US member firm of Deloitte Touche Tohmatsu. Deloitte Touche Tohmatsu is a Swiss Verein (association), and, as such, neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the name "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu" or other related names. The services described herein are provided by the US member firm and not by the Deloitte Touche Tohmatsu Verein. For more information, please visit Deloitte's web site at
www.deloitte.com/us. Deloitte Technology, Media & Telecommunications (TMT) Group
The TMT Group is composed of service professionals who have a wealth of experience serving technology, media and telecommunications companies throughout the world in areas including cable, communications providers, computers and peripherals, entertainment, media and publishing, networking, semiconductors, software, wireless, and related industries. These specialists understand the challenges that these companies face throughout all stages of their business growth cycle and are committed to helping them succeed. Deloitte is a leader in providing strategic, financial and operational assistance to its technology, media and telecommunications clients.
NOTE TO INVESTORS: The rankings set forth in this press release are based solely on past financial performance, and not on expected future performance. Past financial performance is not necessarily indicative of results that may be expected for future periods.
Source: Pharsight Corporation
Contact: Tamra White of Pharsight Corporation, +1-650-314-3809, or twhite@pharsight.com
Pharsight Announces Second Quarter Fiscal Year 2004 Results
TUESDAY, OCTOBER 28, 2003 4:01 PM
MOUNTAIN VIEW, Calif., Oct 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- Pharsight Corporation (PHST) , a leading provider of science and information technology-based software and consulting services to optimize clinical drug development, today announced financial results for its second quarter of fiscal year 2004 ended September 30, 2003. For the second quarter, revenue was $4.0 million, an increase of 21 percent compared with revenue of $3.3 million in the second quarter of fiscal year 2003. The net loss per share attributable to common stockholders improved to $0.05 in the second quarter, compared with a net loss per share attributable to common stockholders of $0.17 for the same period in the prior fiscal year.
"We are pleased with our financial results for the quarter," said Shawn M. O'Connor, president and chief executive officer. "Our focus on revenue growth and expense management has resulted in the reduction of both our net loss and cash used for operations for the second quarter to below $1.0 million and brings the company closer to profitability and cash break-even. Looking forward, we will continue to support our business through providing innovative solutions and consulting support that enable pharmaceutical and biotechnology companies to overcome the time and cost-intensive process of bringing new drugs to market."
Customer Highlights
Pharsight continued to expand its relationship with Pfizer, Inc. During the second quarter, Pharsight signed agreements with Pfizer for additional consulting services, including an agreement with Pfizer Limited in the United Kingdom where Pharsight will extend its consulting services through the next year at that location.
In addition to expanding current relationships, Pharsight added new customers to its growing roster. During the second quarter of fiscal year 2004, Pharsight signed consulting service agreements with three new customers, Angiogenix, Inc., Biogen, Inc. and IDEC Pharmaceuticals.
Pharsight continued to build its customer base for its Knowledgebase Server (PKS) data management software, as the company signed a worldwide PKS licensing agreement with a major pharmaceutical company subsequent to the close of the second quarter.
Product Developments
During the second quarter of fiscal year 2004, Pharsight announced the release of a new version of its Pharsight(R) Knowledgebase Server(TM) (PKS) product. In conjunction with the release of PKS version 2.1, Pharsight unveiled WinNonlin(R) version 4.1 and introduced PKS Reporter(TM) version 1.1 and PKS Data Connector(TM), all of which are part of Pharsight's new PKS suite. The new Pharsight Knowledgebase Suite is designed with important additional enhancements across the entire system. As previously announced in the first quarter, Pharsight entered into an agreement with a major pharmaceutical company to collaborate on the evaluation of Pharsight's Drug Model Explorer(TM) (DMX(TM)), the first component of a new software technology platform being developed by Pharsight to help enable pharmaceutical companies to adopt an integrated, quantitative and model-based approach to clinical drug development. The company reports continued progress and positive input from its collaborator to date, and that the project is moving forward according to plans.
New Employees
In the second quarter Pharsight named Farkad Ezzet, Ph.D., as senior scientist for the company's Strategic Consulting Group. Dr. Ezzet came to Pharsight from Schering-Plough Research Institute in Kenilworth, New Jersey, where he was head of the Pharmacometric Group in the Department of Pharmacokinetics. Before Schering-Plough, Dr. Ezzet held the position of senior clinical pharmacology statistician at Novartis in Basel, Switzerland.
In the third quarter Pharsight named Cynthia Stephens as its Interim Chief Financial Officer. Ms. Stephens replaced Charlie Faas following his departure this month.
Awards
Subsequent to the close of the second quarter, Pharsight announced that it ranked Number 187 on the 2003 Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America. Rankings are based on average percentage revenue growth over five years, from 1998-2002. Pharsight grew 1,836 percent during this period.
In addition to ranking on the Deloitte Technology Fast 500, Pharsight Corporation was also named on the Technology Fast 50, which is a ranking of the 50 fastest growing technology firms in Silicon Valley.
Conference Call
Investors are invited to listen to the Web cast discussion of these and other events by Pharsight management on October 28, 2003 at 2:00 p.m. PST/5:00 p.m. EST. The live Web cast will be conducted by Chief Executive Officer Shawn O'Connor and Interim Chief Financial Officer Cynthia Stephens and may be accessed in the Investor Relations section of Pharsight's Web site:
www.pharsight.com/investor_relations/ir_fincevent.php . A replay will be available from approximately 5:00 p.m. PST on October 28, 2003 until the company's next earnings call in January 2004.
About Pharsight Corporation
Pharsight Corporation develops and markets products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization. By integrating scientific, clinical and business decision criteria into a dynamic, model-based methodology, Pharsight helps its customers optimize the value of their drug development programs and portfolios from discovery to post-launch marketing and any point in between. Pharsight uses computer-based drug-disease models, dynamic predictive market models, clinical trial simulation and advanced valuation models to create a continuously evolving view of its customers' development efforts and product portfolios. This enables decision makers to make explicit value-driven trade-offs throughout the development and commercialization process. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available on the World Wide Web at
www.pharsight.com. The statements in this press release regarding Pharsight's goals and objectives are forward-looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changing economic conditions may affect the demand Pharsight expects for its products and services; changes in Pharsight research and development focus or operating strategies due to new market opportunities or conditions; and other risks disclosed under the caption "Risk Factors" in Pharsight's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on June 10, 2003. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise. Pharsight and WinNonlin are registered trademarks of Pharsight Corporation. Pharsight Knowledgebase Server (PKS), PKS Reporter, PKS Data Connector and Drug Model Explorer are all trademarks of Pharsight Corporation.
